The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 04, 2009
Filed:
Mar. 17, 2003
Miljenko Dumic, Zagreb, HR;
Mladen Vinkovic, Cakovec, HR;
Marina Oresic, Sesvete, HR;
Ernest Mestrovic, Bjelovar, HR;
Aleksandar Danilovski, Rijeka, HR;
Alojz Dumbovic, Zagreb, HR;
Zdravka Knezevic, Zagreb, HR;
Gorjana Lazarevski, Zagreb, HR;
Dominik Cincic, Zagreb, HR;
Darko Filic, Zagreb, HR;
Katica Lazaric, Zagreb, HR;
Dejan Kresimir Bucar, Pusca, HR;
Miljenko Dumic, Zagreb, HR;
Mladen Vinkovic, Cakovec, HR;
Marina Oresic, Sesvete, HR;
Ernest Mestrovic, Bjelovar, HR;
Aleksandar Danilovski, Rijeka, HR;
Alojz Dumbovic, Zagreb, HR;
Zdravka Knezevic, Zagreb, HR;
Gorjana Lazarevski, Zagreb, HR;
Dominik Cincic, Zagreb, HR;
Darko Filic, Zagreb, HR;
Katica Lazaric, Zagreb, HR;
Dejan Kresimir Bucar, Pusca, HR;
Pliva Hrvatska D.O.O., Zagreb, HR;
Abstract
Substantially pure isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A having the Formula I: wherein S is an organic solvent which is at least partially miscible with water, x is 1, 1.25, 1.5 or 2, y is 0, 0.5, or 1, the pseudopolymorph being characterized by the monoclinic space group P2and average unit cell parameters comprising: crystal axis lengths of a=15.5-17.0 Å, b=15.5-17.0 Å, and c=17.5-19.5 Å, and angles between the crystal axes of α=γ=90° and β=106°-112°. In addition, this disclosure is directed to processes for the preparation of the substantially pure isostructural pseudopolymorphs of Formula I; to pharmaceutical compositions containing substantially pure isostructural pseudopolymorphs of Formula I; and to a method for the treatment of bacterial and protozoan infections, and inflammation-related diseases by administration of a pharmaceutical composition containing the substantially pure isostructural pseudopolymorphs of Formula I.